基础医学与临床 ›› 2019, Vol. 39 ›› Issue (10): 1494-1498.
• 短篇综述 • 上一篇 下一篇
邢苗苗,张晓燕,管又飞
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
基金资助:
Received:
Revised:
Online:
Published:
摘要: 奥贝胆酸是一种新型选择性FXR激动剂,在调节胆汁酸代谢及糖脂代谢中发挥着重要的作用,是原发性胆汁性肝硬化以及非酒精性脂肪肝的新型候选药物。奥贝胆酸可通过抑制纤维化进程和抑制炎性反应过程从而缓解疾病。
关键词: 奥贝胆酸, FXR, 原发性胆汁性肝硬化, 非酒精性脂肪肝
Abstract: Obeticholic acid is a novel selective FXR agonist that plays an important role in regulating bile acid metabolism, as well as glucose and lipid metabolism. It is a new drug candidate for primary biliary cirrhosis and nonalcoholic fatty liver disease. A series of studies have shown that obeticholic acid can alleviate the disease by inhibiting the progression of fibrosis and inhibiting the inflammatory process.
Key words: obeticholic ocid, FXR, primary biliary cholangitis, non-alcoholic steatohepatitis
邢苗苗 张晓燕 管又飞. 奥贝胆酸的研究进展[J]. 基础医学与临床, 2019, 39(10): 1494-1498.
/ 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
https://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2019/V39/I10/1494